Medindia
About ▼ Careers Internship MedBlog Contact us
English (US) ▼
Medindia
LOGIN REGISTER
Advertisement

With Life-Threatening Allergies Diagnosed in Infancy, kaléo Announces Availability of First and Only FDA-Approved Epinephrine Auto-Injector (EAI) for Infants and Toddlers Weighing 16.5 to 33 Pounds (7.5 to 15 kilograms)

Thursday, April 26, 2018 Drug News
Advertisement
AUVI-q® (epinephrine injection, USP) 0.1 mg auto-injector is specifically designed for infants and toddlers weighing 16.5 to 33 pounds (7.5 to 15 kilograms)
Advertisement

Like the currently available AUVI-Q (epinephrine injection, USP) 0.15 mg and 0.3 mg, AUVI-q 0.1 mg is about the size of a credit card and the thickness of a cellphone
Sponsored Post and Backlink Submission


Latest Press Release on Drug News

Happy Fruit Redefines Wellness with THCV-Infused Gummies: A Breakthrough in Cannabinoid Innovation and Metabolic Supplements
Unlocking the Power of THCV: Happy Fruit's New Gummies Suppress Appetites and Provide Metabolic Support * OCEANSIDE, Calif. , April 18, 2024 /PRNewswire/ -- Happy Fruit ...
41st International Conference on Drug Discovery and Drug delivery system
On behalf of the organizing committee its great pleasure to invite to all attendees of the "41st International Conference on Drug Discovery and Drug Delivery System" taking place on November...
London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami
LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), hig...
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval  PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq...
SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs
CHICAGO , April 11, 2024 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has bee...
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close